Pembrolizumab Plus Axitinib in the Second-line and Beyond for mRCC

Nazli Dizman, MD, an Internal Medicine Resident at Yale University, spoke with us about the recent study that she contributed to on the combination of pembrolizumab and axitinib as a second- and further-line treatment for metastatic renal cell carcinoma.  She describes the factors that may contribute to a positive outcome in patients when receiving this combination, along with it’s potential to become a standard of care further-line treatment in the future.

View Dr. Dizman’s other comments on the future of further-line mRCC treatments.